ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015
The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Mathematical models of drug-resistant tuberculosis lack bacterial heterogeneity: A systematic review.PLoS pathogens · 2024Pooled it
- Population-level mathematical modeling of antimicrobial resistance: a systematic review.BMC medicine · 2019Pooled it
- Transmissibility and potential for disease progression of drug resistantBMJ (Clinical research ed.) · 2019Trial
- Pattern and prevalence of rifampicin and isoniazid-resistant tuberculosis using genotype MTBDRMicrobiology spectrum · 2026Article
- Multi-drug resistance and compensatory mutations in Mycobacterium tuberculosis in Vietnam.Tropical medicine & international health : TM & IH · 2025Article
- Drivers of antimicrobial resistance in pig production systems of Uganda.Communications earth & environment · 2025Article
- Genomic analysis of lineage-specific transmission of multidrug resistance tuberculosis in China.Emerging microbes & infections · 2024Article
- An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The relative transmission fitness of multidrug-resistant Mycobacterium tuberculosis in a drug resistance hotspot.Nature communications · 2023Article
- High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistantEmerging microbes & infections · 2022Article
- Review
- A CRISPR-guided mutagenic DNA polymerase strategy for the detection of antibiotic-resistant mutations inMolecular therapy. Nucleic acids · 2022Article
- Estimating tuberculosis drug resistance amplification rates in high-burden settings.BMC infectious diseases · 2022Article
- Assessing the Emergence of Resistance in vitro and Invivo: Linezolid Combined with Fosfomycin Against Fosfomycin-Sensitive and ResistantInfection and drug resistance · 2022Article
- Evolution ofFrontiers in cellular and infection microbiology · 2022Review
- Molecular characterization of rpoB gene mutations in isolates from tuberculosis patients in Cubal, Republic of Angola.BMC infectious diseases · 2021Article
- Heterogeneous Streptomycin Resistance Level AmongFrontiers in microbiology · 2021Article
- Characteristics of compensatory mutations in the rpoC gene and their association with compensated transmission of Mycobacterium tuberculosis.Frontiers of medicine · 2020Article
- Projecting the impact of variable MDR-TB transmission efficiency on long-term epidemic trends in South Africa and Vietnam.Scientific reports · 2019Article
- The Importance of Heterogeneity to the Epidemiology of Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDrug resistance poses a serious challenge for the control of tuberculosis in many settings. It is well established that the expected future trend in resistance depends on the reproductive fitness of drug-resistant Mycobacterium tuberculosis. However, the variability in fitness between strains with different resistance-conferring mutations has been largely ignored when making these predictions.
methodsWe developed a novel approach for incorporating the variable fitness costs of drug resistance-conferring mutations and for tracking this distribution of fitness costs over time within a transmission model. We used this approach to describe the effects of realistic fitness cost distributions on the future prevalence of drug-resistant tuberculosis.
resultsThe shape of the distribution of fitness costs was a strong predictor of the long-term prevalence of resistance. While, as expected, lower average fitness costs of drug resistance-conferring mutations were associated with more severe epidemics of drug-resistant tuberculosis, fitness distributions with greater variance also led to higher levels of drug resistance. For example, compared to simulations in which the fitness cost of resistance was fixed, introducing a realistic amount of variance resulted in a 40% increase in prevalence of drug-resistant tuberculosis after 20 years.
conclusionsThe differences in the fitness costs associated with drug resistance-conferring mutations are a key determinant of the future burden of drug-resistant tuberculosis. Future studies that can better establish the range of fitness costs associated with drug resistance-conferring mutations will improve projections and thus facilitate better public health planning efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.